ATE530184T1 - Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe - Google Patents

Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe

Info

Publication number
ATE530184T1
ATE530184T1 AT08105065T AT08105065T ATE530184T1 AT E530184 T1 ATE530184 T1 AT E530184T1 AT 08105065 T AT08105065 T AT 08105065T AT 08105065 T AT08105065 T AT 08105065T AT E530184 T1 ATE530184 T1 AT E530184T1
Authority
AT
Austria
Prior art keywords
tumor
active ingredients
cancer active
compounds
piperazinone
Prior art date
Application number
AT08105065T
Other languages
English (en)
Inventor
Andrew D Hamilton
Said Sebti
Hairuo Peng
Original Assignee
Univ Yale
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Univ South Florida filed Critical Univ Yale
Application granted granted Critical
Publication of ATE530184T1 publication Critical patent/ATE530184T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT08105065T 2001-08-24 2002-08-23 Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe ATE530184T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31479501P 2001-08-24 2001-08-24

Publications (1)

Publication Number Publication Date
ATE530184T1 true ATE530184T1 (de) 2011-11-15

Family

ID=23221472

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02796419T ATE447955T1 (de) 2001-08-24 2002-08-23 Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel
AT08105065T ATE530184T1 (de) 2001-08-24 2002-08-23 Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02796419T ATE447955T1 (de) 2001-08-24 2002-08-23 Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel

Country Status (9)

Country Link
US (1) US7763620B2 (de)
EP (2) EP2014291B1 (de)
JP (1) JP2005504771A (de)
AT (2) ATE447955T1 (de)
AU (1) AU2002332640B2 (de)
CA (1) CA2458009C (de)
DE (1) DE60234354D1 (de)
ES (2) ES2335092T3 (de)
WO (1) WO2003017939A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172685A1 (en) 2006-06-28 2011-07-28 Amgen Inc Glycine transporter-1 inhibitors
WO2009053459A1 (en) 2007-10-26 2009-04-30 Glaxo Group Limited 4-benz0yl-1-substituted-piperazin-2-0ne derivatives as p2x7 modulators
KR100967171B1 (ko) * 2007-12-26 2010-07-05 재단법인서울대학교산학협력재단 Δ5-2-옥소피페라진 유도체 및 그의 고체상 합성 방법
PE20110059A1 (es) * 2008-06-24 2011-02-15 Sanofi Aventis Isoquinolinas e isoquinolinonas sustituidas en calidad de inhibidores de la rho-quinasa
WO2010088457A2 (en) * 2009-01-29 2010-08-05 H. Lee Moffitt Cancer And Research Institute, Inc. Methods for inducing tumor regression, inhibiting tumor growth, and inducing apoptosis in breast tumors with geranylgeranyltransferase i inhibitors
WO2010149943A1 (en) * 2009-06-25 2010-12-29 Oncorel Ab New compounds and medical use
KR101162100B1 (ko) * 2010-01-19 2012-07-02 한미사이언스 주식회사 세포사멸 유도 활성을 갖는 신규 피라지논 유도체 및 이를 활성성분으로 포함하는 약학 조성물
CA2849751C (en) * 2011-10-03 2019-06-11 Euroscreen Sa Chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptormediated disorders and chiral synthesis thereof
EP3698797A1 (de) 2017-10-16 2020-08-26 Tsinghua University -inhibitor des mevalonsäurewegs und pharmazeutische zusammensetzung davon
EP3724178B1 (de) 2017-12-15 2024-05-01 Inthera Bioscience AG 1-(piperidinocarbonylmethyl)-2-oxopiperidin-derivate zur behandlung von krebs
WO2020048831A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
AR116020A1 (es) 2018-09-03 2021-03-25 Bayer Ag COMPUESTOS DE 3,9-DIAZAESPIRO[5.5]UNDECANO COMO INHIBIDORES DE GGTasa I Y SU USO PARA EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2020048830A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
US12611406B2 (en) 2020-06-19 2026-04-28 Inthera Bioscience AG Oxopiperazine derivatives for the treatment of cancer
CN115894609B (zh) * 2022-11-02 2025-04-29 四川大学 一种具有抗癌活性的二肽化合物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47168A (en) * 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
US4251438A (en) 1979-06-14 1981-02-17 The Upjohn Company Piperazinone and piperazine polypeptides
US5284828A (en) * 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
EE9700141A (et) 1994-12-23 1997-12-15 Dr. Karl Thomae Gmbh Piperasiinderivaadid, neid sisaldavad ravimid, nende kasutamine ja valmistamise meetod
US5885995A (en) * 1996-04-03 1999-03-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0951471B1 (de) 1996-12-17 2004-03-17 Warner-Lambert Company Llc Cycloalkyl inhibitoren der protein-farnesyltransferase
WO1999009985A1 (en) * 1997-08-27 1999-03-04 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
YU47600A (sh) 1998-01-27 2002-09-19 Aventis Pharmaceuticals Products Inc. SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa
JP2003529531A (ja) 1998-11-25 2003-10-07 アヴェンティス ファーマシューティカルズ インコーポレイテッド 置換オキソアザへテロシクリルＸａ因子阻害剤
US6358956B1 (en) 1999-03-03 2002-03-19 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
KR20020087041A (ko) * 1999-07-28 2002-11-21 아벤티스 파마슈티칼스 프로덕츠 인크. 치환된 옥소아자헤테로사이클릴 화합물

Also Published As

Publication number Publication date
EP1427418B1 (de) 2009-11-11
EP1427418A4 (de) 2004-11-17
CA2458009C (en) 2011-08-16
ES2335092T3 (es) 2010-03-22
US20080221123A1 (en) 2008-09-11
US7763620B2 (en) 2010-07-27
AU2002332640B2 (en) 2007-11-08
ES2376399T3 (es) 2012-03-13
WO2003017939A3 (en) 2003-11-13
DE60234354D1 (de) 2009-12-24
WO2003017939A2 (en) 2003-03-06
ATE447955T1 (de) 2009-11-15
JP2005504771A (ja) 2005-02-17
EP2014291A3 (de) 2009-06-17
EP1427418A2 (de) 2004-06-16
CA2458009A1 (en) 2003-03-06
EP2014291A2 (de) 2009-01-14
EP2014291B1 (de) 2011-10-26

Similar Documents

Publication Publication Date Title
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
IS2114B (is) Kínasólínafleiður til að meðhöndla æxli
ATE447955T1 (de) Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel
DE69931766D1 (de) Antitumorale mittel
ATE506953T1 (de) 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
ATE555789T1 (de) Pyridazinderivate und deren verwendung als therapeutische mittel
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
WO2003075850A3 (en) Methods for alzheimer's disease treatment and cognitive enhancement
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
BR0113176A (pt) Compostos biciclo-pirazol, composições farmacêuticas compreendendo os compostos, uso dos compostos na fabricação de medicamentos, processos para a preparação dos compostos, coleção quìmica combinatória e métodos para o tratamento de mamìferos incluindo humanos utilizando os compostos
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
NO20014415D0 (no) Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
YU54202A (sh) Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
EP1423107A4 (de) Fettalkohol-arzneimittel-konjugate
EP1819227A4 (de) Pharmazeutische formulierungen von decitabin
EA200200616A1 (ru) Химические производные и их применение в качестве антителомеразного агента
ATE355288T1 (de) Verbindungen und therapeutische methoden
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
EA200401111A1 (ru) Биполярные соли транс-каротиноидов и их применение
ATE302203T1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
BR0201862A (pt) Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties